Search

Bridgebio Pharma Inc

Abierto

SectorSanidad

82.21 1.26

Resumen

Variación precio

24h

Actual

Mínimo

80.75

Máximo

82.54

Métricas clave

By Trading Economics

Ingresos

24M

-167M

Ventas

40M

195M

BPA

-0.84

Margen de beneficios

-85.626

Empleados

834

EBITDA

68M

-113M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+30.25% upside

Dividendos

By Acuity

Próximas Ganancias

4 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

2.4B

16B

Apertura anterior

80.95

Cierre anterior

82.21

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

145 / 340 Clasificación en Healthcare

Bridgebio Pharma Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

21 jul 2026, 23:51 UTC

News
Social Media

Pegasystems shares declined in after-market trading following second-quarter results that missed analyst expectations for earnings and revenue, amid concerns over future ACV growth.

21 jul 2026, 23:46 UTC

News

Adobe Inc. shares are declining in after-market trading following Morgan Stanley's downgrade to "underweight" and a reduced price target of $240.

21 jul 2026, 23:41 UTC

News

Raytheon Technologies secures a $49.7 million Navy contract for weapon system repairs, with shares trading higher in after-market hours.

21 jul 2026, 23:41 UTC

Social Media
News

Capital One Financial reported adjusted EPS of $5.81 and revenue of $15.85 billion, exceeding expectations, as shares rose in after-market trading.

21 jul 2026, 23:41 UTC

Macro News
ETF Constituents
News

Vanguard Information Technology ETF is little changed after market hours, despite broader market gains and negative contributions from Apple, Microsoft, and Nvidia.

21 jul 2026, 23:36 UTC

News
ETF Constituents

The Vanguard Growth ETF is trading roughly flat in after-market hours, reflecting minor fluctuations among its holdings, including declines from Apple, Microsoft, and Nvidia.

21 jul 2026, 23:36 UTC

Social Media
News

Micron Technology rose in after-market hours, supported by a semiconductor rally and a Bank of America upgrade to "buy" on strong AI demand.

21 jul 2026, 23:36 UTC

News

MongoDB shares traded higher after director Dwight Merriman sold 16,000 shares for $5.2 million under a pre-scheduled plan, retaining $496.55 million in holdings.

21 jul 2026, 23:32 UTC

News

United Community Banks Inc. shares rise in after-market trading after an upgrade to Buy, bolstered by Q2 2026 net interest income of $270.7 million.

21 jul 2026, 23:26 UTC

Correlated Moves
News

JPMorgan Chase & Co shares showed little change in after-market hours amid broader market movements. CEO Jamie Dimon raised concerns over geopolitical tensions and inflation.

21 jul 2026, 23:26 UTC

Social Media
Correlated Moves
News

Coinbase Global shares rose in after-market trading amid reports of a regulatory agreement that may benefit digital assets, with Bitcoin approaching $67,000.

21 jul 2026, 23:26 UTC

News

Lucid Group Inc. faces a class action lawsuit over alleged supplier quality issues, contributing to a decline in after-market trading. Shares earlier stabilized after a session low.

21 jul 2026, 23:26 UTC

News

Intuit Inc. shares are lower in after-market trading following a class action lawsuit alleging misleading statements about TurboTax revenue growth and competitive advantages.

21 jul 2026, 23:16 UTC

News

Sprinklr Inc reported first-quarter revenues of $219.5 million, exceeding expectations, but shares are lower in after-market hours amid sector concerns and mixed AI sentiments.

21 jul 2026, 23:16 UTC

News

Nasdaq shares rise in after-market hours following the dismissal of all claims in the Miami International litigation, positively impacting investor sentiment.

21 jul 2026, 23:16 UTC

News

Iridium Communications Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid significant gains in technology and semiconductor stocks in Asia.

21 jul 2026, 23:16 UTC

News

Intel faces valuation scrutiny as modest growth expectations contrast with sector leaders benefiting from AI demand. Shares were roughly flat in after-market hours.

21 jul 2026, 23:11 UTC

News

Toast Inc shares are trading higher in after-market hours following the announcement of its second quarter 2026 financial results release on August 4.

21 jul 2026, 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

21 jul 2026, 23:06 UTC

News

General Motors plans a new generation of gasoline-powered Cadillac models, shifting from an all-electric strategy. Shares are higher in after-market trading.

21 jul 2026, 23:02 UTC

News

Park Aerospace shares lower in after-market hours following the unexpected death of Vice President Daniel McNamara, impacting investor sentiment and contributing to the decline.

21 jul 2026, 23:02 UTC

Event
News

Weatherford International shares advanced in after-market trading following second-quarter results, with revenues of $1.11 billion exceeding expectations despite a decline.

21 jul 2026, 23:02 UTC

News

Jefferies raised its price target on Genuine Parts Co to $130.00, contributing to after-market gains following a dip earlier in the session.

21 jul 2026, 23:02 UTC

Event
News
Social Media

AAR Corp shares are lower in after-market trading following mixed fourth-quarter results and cautious guidance, despite exceeding sales and EPS expectations.

21 jul 2026, 23:02 UTC

News

ServiceNow Inc. shares declined in after-market hours amid concerns about generative AI's impact on the enterprise software sector, according to Morgan Stanley.

21 jul 2026, 23:01 UTC

News
Social Media

Citigroup Inc declared a quarterly dividend of $0.67 per share, though shares are trading lower after-market amid ongoing market weakness.

21 jul 2026, 23:01 UTC

News

Norfolk Southern announced a quarterly dividend of $1.35 per share, contributing to shares trading higher in after-market hours following three lower sessions.

21 jul 2026, 23:01 UTC

News

DigitalOcean shares rise in after-market hours after Baird analyst initiates coverage with an Outperform rating. The stock closed at $119.09 in the prior session.

21 jul 2026, 23:01 UTC

News
Social Media

Chubb Ltd reported second-quarter net income of $2.85 billion, down from $2.97 billion a year earlier, contributing to lower after-market trading.

Comparación entre iguales

Cambio de precio

Bridgebio Pharma Inc previsión

Precio Objetivo

By TipRanks

30.25% repunte

Estimación a 12 Meses

Media 107.39 USD  30.25%

Máximo 157 USD

Mínimo 93 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bridgebio Pharma Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

18

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

145 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.